Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Naltrexone (LDN) for ME/CFS
NCT07285473Phase 2Not yet recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Nov 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sponsored by University of Alabama at Birmingham. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
naltrexone
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT07285473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285473.